세계의 발현 곤란 단백질 시장 보고서(2025년)
Difficult-to-Express Proteins Global Market Report 2025
상품코드 : 1824372
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

발현 곤란 단백질 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 11.5%를 나타내 80억 3,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 새로운 발현 시스템 개발, 차세대 유전자 편집 도구, 무 세포 시스템 개선, 단백질 공학 강화, ai와 머신러닝의 통합으로 인한 것으로 예측됩니다. 예측 기간의 주요 동향에는 혁신적인 단백질 폴딩 기술, 합성 생물학의 이용 확대, 표적 단백질 수식, 생물 물리학적 특성 평가의 진보, CRISPR/CAS 기술의 이용 확대 등이 포함됩니다.

향후 5년간의 성장률 11.5%라고 하는 예측은 전회 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 부과는 한국과 덴마크에서 수입되는 재조합 단백질 생산 시스템 및 생물반응기 부품의 비용을 증가시키고, 생물학적 제제의 개발을 늦추고, 연구개발비를 증가시킬 수 있기 때문에 미국의 바이오의약품에 큰 과제를 초래할 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

예상되는 재조합 단백질 수요의 급증은 당분간 발현 곤란 단백질 시장 확대를 견인하게 될 것입니다. 재조합 단백질은 변형된 DNA를 사용하여 합성되고, 원하는 단백질에 필요한 유전 암호를 생성하는데 중요한 역할을 합니다. 재조합 단백질 합성에 필수적인 이러한 발현 어려운 단백질은 특정 활성, 단백질 간 상호작용의 탐색, 복잡한 병리학을 표적으로 하는 새로운 치료제의 개발을 가능하게 합니다. 예를 들어 Amgen Inc.의 2022년 연례 보고서에서 강조된 바와 같이, 재조합 인간 단일클론항체인 Prolia(데노스맙)는 연간 매출에서 현저한 12% 성장을 경험했으며, 2021년 32억 4,800만 달러에 비해 2022년에는 36억 2,800달러에 달했습니다. 이와 같이 재조합 단백질에 대한 수요 증가는 발현 곤란 단백질 시장 성장의 원동력이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Difficult-to-express proteins, in the realm of biotechnology, refer to proteins that pose challenges in terms of producing them in significant quantities or achieving high yields through standard protein expression systems within heterologous expression systems. These proteins play a crucial role in research endeavors, contributing to the exploration of protein folding and stability, the development of innovative therapeutics, and the conduct of biochemical studies related to drugs.

The primary categories of difficult-to-express proteins encompass proteases, kinases, membrane proteins, and others. Proteases, for instance, are enzymes that catalyze the breakdown of peptide bonds in proteins. They serve as essential tools in peptide research, showcasing proficiency in breaking down proteins into smaller peptide fragments. This capability facilitates simultaneous mass spectrometry analysis and contributes to the understanding and treatment of various diseases such as inflammation, sepsis, digestive disorders, cystic fibrosis, and retinal disorders. The expression of difficult proteins involves diverse techniques, including disulfide-bonded protein expression, membrane protein expression, toxic protein expression, and addressing target protein insolubility. Various technologies, such as cell-free protein synthesis, prokaryotic expression systems, small ubiquitin-such as modifier (SUMO) fusion systems, and gene fusion systems, are employed to address these challenges. The applications span across critical areas such as drug discovery, protein purification, protein therapeutics, and disease diagnostics and monitoring.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The difficult-to-express proteins market research report is one of a series of new reports from The Business Research Company that provides difficult-to-express proteins market statistics, including difficult-to-express proteins industry global market size, regional shares, competitors with a difficult-to-express proteins market share, detailed difficult-to-express proteins market segments, market trends and opportunities, and any further data you may need to thrive in the difficult-to-express proteins industry. This difficult-to-express proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The difficult-to-express proteins market size has grown rapidly in recent years. It will grow from $4.65 billion in 2024 to $5.2 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to rising demand for protein therapeutics, drug development challenges, biopharmaceutical advancements, technological limitations, gene editing and engineering.

The difficult-to-express proteins market size is expected to see rapid growth in the next few years. It will grow to $8.03 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to novel expression systems development, next-generation gene editing tools, improved cell-free systems, enhanced protein engineering, ai and machine learning integration. Major trends in the forecast period include innovative protein folding technologies, expanded use of synthetic biology, targeted protein modification, biophysical characterization advances, increased use of CRISPR/CAS technology.

The forecast of 11.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for U.S. biopharma by increasing costs for recombinant protein production systems and bioreactor components imported from South Korea and Denmark, potentially delaying biologic drug development and raising research and development(R&D) expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated surge in demand for recombinant proteins is poised to drive the expansion of the difficult-to-express protein market in the foreseeable future. Recombinant proteins, synthesized using modified DNA, play a crucial role in generating the genetic codes necessary for desired proteins. These difficult-to-express proteins, integral in recombinant protein synthesis, enable the exploration of specific activities, protein-protein interactions, and the advancement of novel therapeutics targeting complex medical conditions. For instance, as highlighted in Amgen Inc.'s 2022 annual report, Prolia (Denosumab), a recombinant human monoclonal antibody, experienced a notable 12% growth in annual sales, reaching $3,628 million in 2022 compared to $3,248 million in 2021. Thus, the escalating demand for recombinant proteins acts as a driving force behind the growth of the difficult-to-express protein market.

The burgeoning need for biopharmaceuticals is forecasted to fuel the expansion of the difficult-to-express protein market moving forward. Biopharmaceuticals, derived from biological sources rather than chemical synthesis, are at the forefront of this demand surge. Companies investing in advanced technologies and innovative strategies to overcome expression challenges are generating high-quality, functional proteins. For instance, data from the International Trade Administration in July 2022 indicated that the Pharmaceutical Research and Manufacturers Association (PhRMA) reported approximately $97 billion in research and development spending by biopharmaceutical firms in the U.S. Consequently, the escalating demand for biopharmaceuticals is a significant driver behind the growth of the difficult-to-express protein market.

The difficult-to-express protein market is witnessing a significant trend focused on the development of pioneering technologies. Key companies within this sector are directing their efforts towards innovating technologies to maintain their market foothold. For instance, in January 2023, Evozyne, a biotechnology firm based in the United States, introduced a groundbreaking AI model named Protein Transformer Variational AutoEncoder. This technology serves as a framework adept at effectively training and deploying large language models tailored for biology. The resulting model represents an innovative application of deep learning, presenting new prospects for the data-driven creation of engineered proteins designed with specific functionalities.

A prevalent trend gaining momentum in the difficult-to-express protein market is the substantial increase in investment directed toward enhancing production capacities. For example, in July 2023, Biovian Oy, a Finland-based Contract Development and Manufacturing Organization (CDMO) specializing in biopharmaceuticals, disclosed a significant investment exceeding €50 million ($53.249 million) to expand its manufacturing facility in Finland. This strategic investment aims to meet the escalating demand for top-tier biopharmaceutical manufacturing services, further solidifying Biovian's position as a reliable partner in the biopharmaceutical industry. The expansion, in conjunction with Biovian's existing facility, will amplify the total area to 111,500 square meters, positioning the company to cater effectively to market demands.

In March 2022, Cobepa Inc., a privately held investment company based in the United States, successfully acquired Reaction Biology Corporation for an undisclosed amount. This strategic acquisition by Cobepa Inc. is intended to provide additional capital and resources to further strengthen Reaction Biology Corporation's capabilities in addressing the dynamic requirements of the biopharmaceutical industry. Reaction Biology Corporation is a biopharmaceutical company based in the United States, specializing in the production of difficult-to-express proteins.

Major companies operating in the difficult-to-express proteins market include Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group Ltd, Catalent Inc., Sartorius AG, Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Samsung Biologics Co. Ltd., Bio-Techne Corp., GenScript Biotech Corporation, Ajinomoto Bio-Pharma Services, Novasep Holding SAS, Rentschler Biopharma SE, BioLegend Inc., Codexis Inc., Enzo Biochem Inc., Sino Biological Inc., Horizon Discovery Ltd., Creative Biolabs Inc., OriGene Technologies Inc., Celonic AG, Cube Biotech GmbH, Lucigen Corporation, Batavia Biosciences Inc., Cytovance Biologics Inc., Alloy Therapeutics Inc., Aragen Bioscience Inc., Selexis SA, LifeSensors Inc., Bionova Scientific Inc.

North America was the largest region in the difficult-to-express proteins market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the difficult-to-express proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the difficult-to-express proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The difficult-to-express proteins market consists of revenues earned by entities by providing code optimization, fusion tags, post-translational modification, inducible expression systems, and co-expression chaperones. The market value includes the value of related goods sold by the service provider or included within the service offering. The difficult-to-express protein market also includes the sales of toxoids, antibody fragments, multi-domain proteins, and post-translational modified proteins. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Difficult-to-Express Proteins Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on difficult-to-express proteins market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for difficult-to-express proteins ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The difficult-to-express proteins market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Difficult-to-Express Proteins Market Characteristics

3. Difficult-to-Express Proteins Market Trends And Strategies

4. Difficult-to-Express Proteins Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Difficult-to-Express Proteins Growth Analysis And Strategic Analysis Framework

6. Difficult-to-Express Proteins Market Segmentation

7. Difficult-to-Express Proteins Market Regional And Country Analysis

8. Asia-Pacific Difficult-to-Express Proteins Market

9. China Difficult-to-Express Proteins Market

10. India Difficult-to-Express Proteins Market

11. Japan Difficult-to-Express Proteins Market

12. Australia Difficult-to-Express Proteins Market

13. Indonesia Difficult-to-Express Proteins Market

14. South Korea Difficult-to-Express Proteins Market

15. Western Europe Difficult-to-Express Proteins Market

16. UK Difficult-to-Express Proteins Market

17. Germany Difficult-to-Express Proteins Market

18. France Difficult-to-Express Proteins Market

19. Italy Difficult-to-Express Proteins Market

20. Spain Difficult-to-Express Proteins Market

21. Eastern Europe Difficult-to-Express Proteins Market

22. Russia Difficult-to-Express Proteins Market

23. North America Difficult-to-Express Proteins Market

24. USA Difficult-to-Express Proteins Market

25. Canada Difficult-to-Express Proteins Market

26. South America Difficult-to-Express Proteins Market

27. Brazil Difficult-to-Express Proteins Market

28. Middle East Difficult-to-Express Proteins Market

29. Africa Difficult-to-Express Proteins Market

30. Difficult-to-Express Proteins Market Competitive Landscape And Company Profiles

31. Difficult-to-Express Proteins Market Other Major And Innovative Companies

32. Global Difficult-to-Express Proteins Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Difficult-to-Express Proteins Market

34. Recent Developments In The Difficult-to-Express Proteins Market

35. Difficult-to-Express Proteins Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기